- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶Biomarker Signal Report
- ▶Resistance Mechanism Digest
- ▶Combination Strategy Scan
Oncology literature grows faster than any other therapeutic area — over 150,000 new papers annually. BD teams miss emerging targets; translational scientists duplicate experiments already underway. Lumaris compresses months of systematic review into a structured, decision-ready report.
Suggested cadence: Monthly or Quarterly
- ▶Target Landscape Report
- ▶Neuroinflammation Signal Report
- ▶Biomarker & Imaging Endpoint Digest
- ▶Competitive Pipeline Monitor
- ▶Blood-Brain Barrier Delivery Watch
CNS drug development has the highest clinical failure rate of any therapeutic area (>95%). Lumaris surfaces inflection points — which biological hypotheses are gaining or losing support — before they become consensus.
Suggested cadence: Quarterly or Monthly (Enterprise)
- ▶Disease Landscape Report
- ▶Genetic Target Signal Report
- ▶Gene & Cell Therapy Pipeline Tracker
- ▶Regulatory & Designation Intelligence
- ▶Patient Registry & Natural History Gap Analysis
A missed competitor program in a 5,000-patient indication can derail an entire development investment. Lumaris delivers current intelligence on natural history data, competitive positioning, and evolving regulatory precedent.
Suggested cadence: Quarterly (new programs) / Monthly (active development)
04
Immunology & Inflammation
- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶Biomarker Signal Report
- ▶Mechanism-of-Action Deep Dive
- ▶Precision Immunology Watch
Immunology is the most crowded space in pharma. New mechanisms face intense differentiation pressure. Teams need continuous intelligence on what makes a new target viable and which mechanisms are hitting unexpected safety signals in late-stage trials.
Suggested cadence: Monthly
05
Cardiovascular & Metabolic
- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶GLP-1/Incretin Field Monitor
- ▶Cardiovascular Outcome Trial Watch
- ▶Biomarker & Endpoint Intelligence
GLP-1 alone restructured the entire cardiometabolic landscape in 36 months. Staying current on where the science is moving is no longer optional — it is competitive survival.
Suggested cadence: Monthly (high publication velocity)
06
Infectious Disease & Vaccines
- ▶Pathogen Landscape Report
- ▶Vaccine Antigen & Platform Intelligence
- ▶Antimicrobial Resistance (AMR) Monitor
- ▶Pandemic Preparedness Watch
- ▶Competitive Pipeline Monitor
Infectious disease moves on biological timelines, not development timelines. Resistance emerges mid-trial; a new outbreak changes the regulatory landscape overnight. Lumaris provides structured early-warning intelligence.
Suggested cadence: Monthly (AMR/Pandemic Watch) / Quarterly (Pipeline Monitor)
07
Respiratory & Pulmonology
- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶Fibrosis Mechanism Watch
- ▶Biomarker Signal Report
- ▶CFTR & Rare Lung Disease Tracker
Respiratory is bifurcating into precision and broad-population strategies. Teams need intelligence on which biomarker-defined subpopulations represent actionable opportunities and which mechanisms have failed to translate.
Suggested cadence: Quarterly / Monthly (Enterprise)
- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶Gene Therapy & Delivery Platform Watch
- ▶Anti-VEGF Extension & Durability Report
- ▶Dry AMD & Geographic Atrophy Intelligence
Ophthalmology is experiencing a structural shift — from repeated intravitreal injections to durable gene therapies. Teams need intelligence on which delivery platforms are proving out in human trials.
Suggested cadence: Quarterly
09
Gene Therapy & Advanced Modalities
- ▶Platform Technology Landscape
- ▶Delivery Innovation Watch
- ▶Regulatory & Manufacturing Intelligence
- ▶Competitive Pipeline Monitor
- ▶Safety Signal Digest
Gene therapy science is advancing at platform speed, but regulatory and manufacturing constraints are evolving in parallel. Lumaris gives teams a structured view of platform choices, delivery constraints, and the safety signals regulators are watching most closely.
Suggested cadence: Quarterly / Monthly (Enterprise)
10
Women's Health & Reproductive
- ▶Target Landscape Report
- ▶Competitive Pipeline Monitor
- ▶Hormonal Biology Advances Watch
- ▶Endometriosis & Uterine Disease Intelligence
- ▶Femtech & Biomarker Signal Report
Women's health has been chronically under-resourced in pharma R&D. The regulatory and market environment is now shifting — creating a window for first-mover programs. Lumaris helps teams identify newly validated targets and competitive white space.
Suggested cadence: Quarterly
- ▶NASH/MASH Pipeline Intelligence
- ▶Fibrosis Pathway Report
- ▶Non-Invasive Biomarker & Endpoint Watch
- ▶Competitive Pipeline Monitor
- ▶Combination Rationale Report
NASH/MASH has become a graveyard of Phase III programs. Teams re-entering or already active in MASH need rigorous intelligence on validated endpoints, failed mechanisms, and combination-therapy evidence. Getting this wrong costs $500M+.
Suggested cadence: Monthly (highly active field)
12
Hematology & Rare Blood Disorders
- ▶Target Landscape Report
- ▶Gene & Cell Therapy Pipeline Tracker
- ▶Competitive Pipeline Monitor
- ▶Post-Approval Evidence Watch
- ▶Erythropoiesis & Clonal Hematopoiesis Signal Report
Hematology has transformed faster than almost any other area — two curative gene therapies for sickle cell approved in the same month in 2023. Teams need structured intelligence on long-term durability data and next-generation CRISPR approaches as they emerge.
Suggested cadence: Quarterly / Monthly (Enterprise)